仁和药业(000650) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was CNY 1,311,390,192.42, representing a 7.66% increase compared to CNY 1,218,062,759.09 in the same period last year[4] - Net profit attributable to shareholders was CNY 155,695,612.25, a 1.95% increase from CNY 152,722,895.57 in the previous year[4] - Total operating revenue for the current period reached ¥1,311,390,192.42, an increase of 7.63% compared to ¥1,218,062,759.09 in the previous period[27] - Net profit for the current period was ¥194,265,657.36, representing a 7.4% increase from ¥180,594,218.41 in the previous period[30] - Earnings per share (EPS) for the current period was ¥0.1112, compared to ¥0.1091 in the previous period[33] Cash Flow - The net cash flow from operating activities was negative at CNY -98,462,253.02, a significant decrease of 37,523.66% compared to the previous year[4] - The net cash flow from operating activities was -98,462,253.02, compared to -261,703.00 in the previous period, indicating a significant decline in operational cash flow[37] - The total cash inflow from operating activities was 1,069,263,178.46, slightly up from 1,042,768,295.40 in the previous period, showing a modest growth[37] - The cash paid for taxes was 182,729,198.75, significantly higher than 88,206,326.69 in the previous period, indicating an increase of over 106%[37] - The net increase in cash and cash equivalents was -1,071,628,585.57, compared to -528,902,253.21 in the previous period, reflecting a worsening cash position[40] Assets and Liabilities - Total assets at the end of the reporting period were CNY 7,067,966,715.56, up 2.32% from CNY 6,907,891,889.07 at the end of the previous year[4] - The total current assets increased from ¥4,055,655,994.38 to ¥4,240,656,169.66, representing a growth of about 4.56%[19] - The total liabilities decreased from ¥968,661,533.16 to ¥924,931,243.59, a decline of about 4.5%[22] - The total liabilities amounted to ¥946,808,327.39, a decrease from ¥980,999,158.26 in the previous period[25] Shareholder Information - The total number of common shareholders at the end of the reporting period was 110,746[11] - The largest shareholder, Renhe (Group) Development Co., Ltd., holds 23.24% of the shares, totaling 325,299,386 shares[11] - The company has a total of 10 major shareholders with varying ownership percentages, with the top three holding a combined total of 30.76%[11] Income and Expenses - The company reported a 197.52% increase in other income to CNY 18,220,799.28, primarily from funding for traditional Chinese medicine projects[10] - The company experienced a 72.29% decrease in interest income to CNY 4,634,602.62, attributed to fewer large certificates of deposit compared to the previous year[10] - Total operating costs amounted to ¥1,072,883,127.77, up 7.8% from ¥995,248,818.55 in the prior period[27] - Research and development expenses for the current period were ¥14,092,315.49, up from ¥11,404,329.12 in the previous period, indicating a focus on innovation[30] Cash and Cash Equivalents - Cash and cash equivalents decreased by 45.40% to CNY 1,288,794,795.96, primarily due to cash purchases of financial products[7] - The company's cash and cash equivalents decreased from ¥2,360,423,381.53 at the beginning of the year to ¥1,288,794,795.96 at the end of the reporting period, a decline of approximately 45.4%[19] - The cash and cash equivalents at the end of the period stood at 1,288,794,795.96, compared to 1,196,732,260.38 at the end of the previous period, indicating an increase of approximately 7.7%[40]